LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
- Home
- esmo conference 2020
- leap 005 NCT03797326 esmo 2020
LEAP-005 Results at ESMO 2020
Abstract No : Abstract #LBA41
Indication : Gastric Cancer, Colorectal Cancer, Biliary tract cancer, Glioblastoma, Ovarian Cancer, Breast cancer
Intervention : Lenvatinib
Company : Merck & Co.
Technology : multiTKI
Results:
187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable
Conclusion:
187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable
Executive Summary
In the interim analysis, prespecified futility efficacy criteria for cohort expansion were met or exceeded, toxicity were manageable in all cohorts. In gastric cancer, ORR: 10%, DCR: 48%. Median PFS: 2.5 months, 6-month rate: 22.2%. Current results show promising efficacy and warrants further randomized trials.